Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use SUTENT safely and effectively. See full prescribing information for SUTENT. SUTENT® (sunitinib malate) capsules, for oral use Initial U.S. Approval: 2006
Medication labelWhy this: Advisory · dailymed-prescription
SUTENT is indicated for the treatment of adult patients with gastrointestinal stromal tumor (GIST) after disease progression on or intolerance to imatinib mesylate. SUTENT is indicated for the treatment of adult patients with advanced renal cell carcinoma (RCC). SUTENT is indicated for the adjuvant treatment of adult patients at high risk of recurrent RCC following nephrectomy. SUTENT is indicated for the treatment of progressive, well-differentiated pancreatic neuroendocrine tumors (pNET) in adult patients with unresectable locally advanced or metastatic disease.
- generic_name
- sunitinib malate
- product_names
- Sunitinib malate
- ndc
- 0069-0550, 0069-0770, 0069-0830, 0069-0980, 0069-0550-38, 0069-0770-38, 0069-0980-38, 0069-0830-38
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en